Canagliflozin antidiabetic drugs

Invokana



Trial Studied treatment Control Patients Size Study type Results NCT

Diabetes type 2 - SGLT2 inhibitors in all type of patients - glucose lowering for cardiovascular prevention in all type of patients

3005: monotherapy ongoing canagliflozinplaceboNA
CANVAS, 2017canagliflozinplacebo10142 (5795/4347) Exploratory NCT01032629
CANTATA-D ongoing canagliflozinplacebo (add-on MET)NA NCT01106677
3009: Add-on to MET ongoing canagliflozinplacebo (add-on MET)NA
3008: Add-on to insulin ongoing canagliflozinplacebo (add-on MET)NA
3015: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU)NA
3002: Add-on to MET + SU ongoing canagliflozinplacebo (add-on MET+SU)NA
3012: Add-on to MET +TZD ongoing canagliflozinplacebo (add-on MET+TZD)NA
3008: Add-on to SU ongoing canagliflozinplacebo (add-on SU)NA